Kanser Hastalarında Demir Eksikliği ve Yönetimi

Busti F, Marchi G, Ugolini S, Castagna A, Girelli D. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals. 2018 Sep 30;11(4):94.

Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol E Hemoter. 2016 Oct;38 (4):325–30.

Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020 Aug 13;136(7):801–13.

Grotto HZW. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol Northwood Lond Engl. 2008;25(1):12–21.

Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001 Jun 15;91(12):2214–21.

Morine Y, Shimada M, Utsunomiya T, Imura S, Ikemoto T, Mori H, et al. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2011;58(110–111):1439–44.

Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SNJ, Starostik P, et al. Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res. 2011 May;35(5):579–84.

Schito L, Semenza GL. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression.Trends Cancer.2016 Dec;2 (12):758–70.

Gaspar BL, Sharma P, Das R. Anemia in malignancies: pathogenetic and diagnostic considerations. Hematol Amst Neth. 2015 Jan;20(1):18–25.

Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999 Dec 23;341(26):1986–95.

Koh JS, Song IC. Functional iron deficiency anemia in patients with cancer. Blood Res. 2024 Dec;59(1):26.

Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer Oxf Engl 1990. 2004 Oct;40(15):2293–306.

Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011 Sep 22;118(12):3222–7.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005 Mar 10;352(10):1011–23.

Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol Baltim Md 1950. 2002 Aug 15;169(4):2204–9.

Abiri B, Vafa M. Iron Deficiency and Anemia in Cancer Patients: The Role of Iron Treatment in Anemic Cancer Patients. Nutr Cancer. 2020 Jul 3;72(5):864–72.

Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010 Dec 2;116(23):4754–61.

Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet Lond Engl. 1996 Oct 12;348(9033):992–6.

Brownlie T, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004 Mar;79(3):437–43.

Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15;95(4):888–95.

Thompson MR, O’Leary DP, Flashman K, Asiimwe A, Ellis BG, Senapati A. Clinical assessment to determine the risk of bowel cancer using Symptoms, Age, Mass and Iron deficiency anaemia (SAMI). Br J Surg. 2017 Sep;104(10):1393–404.

Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. The Oncologist. 2004;9 Suppl 5:4–9.

Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. The Oncologist. 2002;7(6):492–508.

Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2007 Feb 1;64(3 Suppl 2):S5-13; quiz S28-30.

NCCN Clinical Practice Guidelines in Oncology Version 1.2025, Management of Cancer- and Chemotherapy-Induced Anemia.

Murphy WG. The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev. 2014 Mar;28(2):41–7.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct;29:iv96–110.

Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, Diehl LF. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med. 1994 Aug 15;121(4):278–230.

Rawn J. The silent risks of blood transfusion. Curr Opin Anaesthesiol. 2008 Oct;21(5):664–8.

Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009 Apr 9;113(15):3406–17.

Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 2015 Dec;127(23–24):907–19.

Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475–91.

Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010;2010:338–47.

Keating GM. Ferric Carboxymaltose: A Review of Its Use in Iron Deficiency. Drugs. 2015 Jan 1;75(1):101–27.

Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it SaFe2+ ? . J Natl Compr Cancer Netw JNCCN. 2012 May;10(5):669–76.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD007303.

Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol Off J Am Soc Clin Oncol. 2001 Jun 1;19(11):2875–82.

Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Nov 20;28(33):4996–5010.